The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | Strategies to overcome the immunologically “cold” tumor microenvironment of MSS CRC
Guglielmo Vetere, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses immunotherapeutic stategies to overcome the immunologically “”cold”” tumor microenvironment in microsatellite stable colorectal cancer (CRC). Interest focuses on non-liver metastasis patients, testing next-generation PD-1/CTLA-4 agents and targeted therapy combinations. The STELLAR-303 trial (NCT05425940) showed multi-tyrosine kinase inhibitor plus immunotherapy was superior to regorafenib. However, specific subpopulations achieving clinically meaningful benefit remain unclear, and require further investigation. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
